Open Label Ustekinumab for the treatment of anti-TNFα refractory moderate-to-severe Crohn's disease: Follow up of a cohort of patients at an academic inflammatory bowel disease center: P-4.


    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.


    loading  Loading Related Articles